← vista completa

Published on March 1, 2009 | http://doi.org/10.5867/medwave.2009.03.3833

Management of comorbidities in obesity I: cancer, hypertension and diabetes

Manejo de las comorbilidades en la obesidad I: cáncer, hipertensión y diabetes

Robert Eckel

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Robert Eckel

School of Medicine, University of Colorado, Denver, Estados Unidos

Figures

Article has no figures.

Forum

No messages

History

Citation Eckel R. Management of comorbidities in obesity I: cancer, hypertension and diabetes. Medwave 2009;9(03):e3833 doi: 10.5867/medwave.2009.03.3833

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/03/2009

Index

Metrics

Not available at the moment.

Notes

References

  1. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008 Feb 16;371(9612):569-78. | CrossRef | PubMed
  2. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000 Dec;8(9):605-19. | CrossRef | PubMed
  3. Narkiewicz K. Diagnosis and management of hypertension in obesity. Obes Rev. 2006 May;7(2):155-62. | CrossRef | PubMed
  4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. | CrossRef | PubMed
  5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. Epub 2003 May 14. | CrossRef | PubMed
  6. Bakris GL, Weir MR, Black HR. Improving blood pressure control rates: is there more we can do? J Clin Hypertens (Greenwich). 2007 Feb;9(2):134-42. | CrossRef | PubMed
  7. Ramlo-Halsted B, Edelman S. The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies. Clinical Diabetes. 2000; 18 (2). | Link
  8. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003 Oct;26(10):2929-40. | CrossRef | PubMed
  9. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B; et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract. 2005 Nov;59(11):1345-55. | CrossRef | PubMed
  10. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007 Aug;30(8):1979-87. Epub 2007 May 7. | CrossRef | PubMed
  11. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007 Mar;30(3):753-9. | CrossRef | PubMed